Regeneron Beats Estimates but Shares Fall on Eylea Weakness
Regeneron beat profit estimates on strong demand for its eczema drug Dupixent. Shares fell as Eylea sales declined and the FDA delayed a new syringe version.
Xurve View
Insights:
Xurve View
REGENERON PHARMACEUTICALS beat Q1 estimates with adjusted profit of $9.47 per share, though shares fell 6% following lower eye-drug sales. Strong demand for eczema treatment Dupixent offset a 10% decline in Eylea sales, which totaled $941 million. Investors are pivoting focus toward pipeline timelines as Eylea faces rising competition and regulatory delays in the United States.
